Ultime notizie per vTv Therapeutics (NASDAQ:VTVT) Azioni

vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics Inc

Earnings

News

VTVT

vTv Therapeutics Q2 2024 EPS $(0.81)

U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday.
The Dow traded down 0.04% to 40,571.88 while the NASDAQ rose 0.16% to 17,385.52. The S&amp;P 500 also rose, gaining, 0.16% to 5,467.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007912/top-4-energy-stocks-that-may-rocket-higher-in-q3">Top 4 Energy Stocks That May Rocket Higher In Q3</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Monday.
In trading on Monday, energy shares fell by 1.2%.
Top Headline
The Dallas Fed Manufacturing index declined to -17.5 in July versus a reading of -15.1 in the prior month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares shot up 123% to $0.9265 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Shares of NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) got a boost, surging 38% to $0.2618 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares were also up, gaining 26% to $0.8169 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
</ul>
Equities Trading DOWN
<ul>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dropped to $15.92 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>Shares of Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) were down 35% to $1.5350. Cognition Therapeutics reported that participants in the proof-of-concept Phase 2 ‘SHINE' study who were treated with CT1812 for six months showed a consistent trend in cognitive improvement compared to placebo across all cognitive measures.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) was down, falling 21% to $2.3350. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/40006889/this-analyst-with-84-accuracy-rate-sees-more-than-10-upside-in-apple-here-are-5-stock-picks-for-last">This Analyst With 84% Accuracy Rate Sees More Than 10% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a> 
Commodities In commodity news, oil traded down 2.2% to $75.50 while gold traded down 0.2% at $2,376.50.
Silver traded down 1% to $27.75 on Monday, while copper fell 1% to $4.0820.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.20%, Germany's DAX fell 0.53% and France's CAC 40 fell 0.98%. Spain's IBEX 35 Index fell 0.43%, while London's FTSE 100 rose 0.08%.
UK's net consumer credit increased by £1.2 billion over a month during June, a decline from the £1.5 billion gain recorded in May.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 surging 2.13%, Hong Kong's Hang Seng Index gaining 1.28%, China's Shanghai Composite Index gaining 0.03% and India's S&amp;P BSE Sensex rising 0.03%.
Singapore's Domestic Supply Price Index increased by 4.3% year-over-year in June, accelerating from a revised 2.7% gain in the prior month. Producer prices in Malaysia increased to 1.6% year-over-year for June. Profits earned by Chinese industrial firms climbed by 3.5% year-over-year to CNY 3,511.03 billion during the first six months of 2024.
Economics
The Dallas Fed Manufacturing index declined to -17.5 in July versus a reading of -15.1 in the prior month.
Now Read This: <a href="https://www.benzinga.com/news/24/07/40008023/northrop-grumman-to-rally-around-20-here-are-10-top-analyst-forecasts-for-monday">Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday</a>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CGTX

LIPO

NLSP

VERO

VTYX

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Shares of Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) fell sharply during Monday's session after the company reported <a href="https://www.benzinga.com/quote/BMRC/earnings">worse-than-expected quarterly earnings.</a>
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares climbed 128% to $2.8535.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) gained 61.6% to $4.75 after jumping around 56% on Friday.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 37.8% to $0.6232 after gaining 11% on Friday.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) gained 34.4% to $12.25.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 26.8% to $14.76.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) jumped 24.2% to $0.4366.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) rose 23.5% to $2.9860.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) rose 18.4% to $4.19.</li>
<li>Cepton, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 16.1% to $15.35.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) gained 9.5% to $5.09.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 28.6% to $0.1830 after gaining 6% on Friday.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) fell 26.4% to $14.90 following downbeat quarterly results.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) declined 18.5% to $8.84.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 17.5% to $0.2544.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 17% to $1.5243.</li>
<li>Integra Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#NYSE">ITRG</a>) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 12.8% to $14.01.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) fell 10.5% to $9.60.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) fell 6.3% to $37.53.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40011559/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Movers

AVXL

BMRC

CERO

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LUXH

MESO

NIPG

NISN

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.
The Dow traded up 0.02% to 40,598.43 while the NASDAQ rose 0.40% to 17,427.58. The S&amp;P 500 also rose, gaining, 0.28% to 5,474.27.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007912/top-4-energy-stocks-that-may-rocket-higher-in-q3">Top 4 Energy Stocks That May Rocket Higher In Q3</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1% on Monday.
In trading on Monday, energy shares fell by 1.3%.
Top Headline
ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) reported better-than-expected second quarter financial results.
ON Semiconductor reported a fiscal second-quarter 2024 revenue decline of 17.2% year-on-year to $1.74 billion, beating the analyst consensus estimate of $1.73 billion. The adjusted EPS of 96 cents beat the analyst consensus estimate of 92 cents per share, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares shot up 127% to $0.9334 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Shares of NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) got a boost, surging 54% to $0.2794 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares were also up, gaining 16% to $0.75 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
</ul>
Equities Trading DOWN
<ul>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dropped 31% to $14.65 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>Shares of Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) were down 35% to $1.5499 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) was down, falling 25% to $2.22. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/40006889/this-analyst-with-84-accuracy-rate-sees-more-than-10-upside-in-apple-here-are-5-stock-picks-for-last">This Analyst With 84% Accuracy Rate Sees More Than 10% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a> 
Commodities In commodity news, oil traded down 1.9% to $75.71 while gold traded down 0.4% at $2,371.10.
Silver traded down 1.6% to $27.575 on Monday, while copper fell 1.4% to $4.0670.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.23%, Germany's DAX fell 0.58% and France's CAC 40 fell 0.99%. Spain's IBEX 35 Index fell 0.48%, while London's FTSE 100 rose 0.17%.
UK's net consumer credit increased by £1.2 billion over a month during June, a decline from the £1.5 billion gain recorded in May.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 surging 2.13%, Hong Kong's Hang Seng Index gaining 1.28%, China's Shanghai Composite Index gaining 0.03% and India's S&amp;P BSE Sensex rising 0.03%.
Singapore's Domestic Supply Price Index increased by 4.3% year-over-year in June, accelerating from a revised 2.7% gain in the prior month. Producer prices in Malaysia increased to 1.6% year-over-year for June. Profits earned by Chinese industrial firms climbed by 3.5% year-over-year to CNY 3,511.03 billion during the first six months of 2024.
Economics
The Dallas Fed Manufacturing index declined to -17.5 in July versus a reading of -15.1 in the prior month.
Now Read This: <a href="https://www.benzinga.com/news/24/07/40008023/northrop-grumman-to-rally-around-20-here-are-10-top-analyst-forecasts-for-monday">Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday </a>

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin&nbsp;clinical program, which includes the ongoing CATT1 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39993546/vtv-therapeutics-announces-cadisegliatin-program-for-type-1-diabetes-placed-on-clinical-hold" rel="noreferrer noopener">Phase 3 trial in type 1 diabetes</a>.&nbsp;
Cadisegliatin&nbsp;is an oral, liver-selective, glucokinase activator. The company says the drug candidate has been well-tolerated in over 500 subjects to date with up to six months of treatment.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37372919/why-is-diabetes-focused-vtv-therapeutics-stock-trading-higher-today" rel="noreferrer noopener">Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?</a>
Selectively acting on the liver,&nbsp;cadisegliatin&nbsp;increases the activity of glucokinase independently from insulin to improve glycemic control through hepatic glucose uptake and glycogen storage.
The clinical hold was based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of&nbsp;cadisegliatin&nbsp;that could not be resolved by standard mass spectroscopy.
The agency requires a single in vitro study to characterize this signal before the cadisegliatin&nbsp;program can resume.
No patient had been dosed in CATT1 at the time of the clinical hold, and past clinical studies did not reveal any clinically concerning safety issues.
&#8220;We are working diligently with the agency to resolve the clinical hold and resume enrollment as quickly as possible,&#8221; said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics.
Price Action: VTVT stock is down 32.2% at $14.38&nbsp;at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/40009941/neurodegenerative-disease-focused-anavex-life-sciences-alzheimers-candidate-slows-disease-progres" target="_blank" rel="noreferrer noopener">Neurodegenerative Disease-Focused Anavex Life Sciences&#8217; Alzheimer&#8217;s Candidate Slows Disease Progression By Almost 39%</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a target="_blank" href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" rel="noreferrer noopener">Benzinga SmallCAP Conference</a>&nbsp;on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

Biotech

Health Care

General

FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 1% on Monday.
Following the market opening Monday, the Dow traded up 0.06% to 40,612.10 while the NASDAQ rose 1% to 17,529.39. The S&amp;P 500 also rose, gaining, 0.50% to 5,486.56.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007912/top-4-energy-stocks-that-may-rocket-higher-in-q3">Top 4 Energy Stocks That May Rocket Higher In Q3</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.1% on Monday.
In trading on Monday, energy shares fell by 0.9%.
Top Headline
McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) posted worse-than-expected second-quarter financial results.
McDonald&#8217;s reported a second-quarter FY24 sales decline of 0.12% year-on-year to $6.490 billion, missing the analyst consensus of $6.608 billion. Adjusted EPS of $2.97 missed the analyst consensus estimate of $3.07.
Global comparable sales decreased 1.0%, while U.S. comparable sales slipped 0.7%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares shot up 183% to $1.1741 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Shares of Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) got a boost, surging 81% to $5.33 after jumping around 56% on Friday.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares were also up, gaining 65% to $2.06.</li>
</ul>
Equities Trading DOWN
<ul>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dropped 39% to $13.00 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>Shares of Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) were down 37% to $1.49 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) was down, falling 32% to $0.1742 after gaining 6% on Friday.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/40006889/this-analyst-with-84-accuracy-rate-sees-more-than-10-upside-in-apple-here-are-5-stock-picks-for-last">This Analyst With 84% Accuracy Rate Sees More Than 10% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Commodities In commodity news, oil traded up 0.1% to $77.18 while gold traded up 0.4% at $2,389.90.
Silver traded up 0.2% to $28.075 on Monday, while copper fell 1.1% to $4.0775.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 1%, Germany's DAX fell 0.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 rose 0.5%.
UK's net consumer credit increased by £1.2 billion over a month during June, a decline from the £1.5 billion gain recorded in May.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 surging 2.13%, Hong Kong's Hang Seng Index gaining 1.28%, China's Shanghai Composite Index gaining 0.03% and India's S&amp;P BSE Sensex rising 0.03%.
Singapore's Domestic Supply Price Index increased by 4.3% year-over-year in June, accelerating from a revised 2.7% gain in the prior month. Producer prices in Malaysia increased to 1.6% year-over-year for June. Profits earned by Chinese industrial firms climbed by 3.5% year-over-year to CNY 3,511.03 billion during the first six months of 2024.
Economics
The Dallas Fed Manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40008023/northrop-grumman-to-rally-around-20-here-are-10-top-analyst-forecasts-for-monday">Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>

Nasdaq Gains 1%; McDonald's Posts Downbeat Results

WIIM

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.

Shares of Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its <a href="https://www.benzinga.com/quote/PBI/news">e-commerce business to Stord</a>.
Pitney Bowes shares jumped 12.5% to $7.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) gained 46% to $3.45 in pre-market trading after the company announced that it will host an investor presentation to discuss results from its phase 2 SHINE study of CT1812 on Monday July 29, 2024.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares climbed 36.3% to $4.69 in pre-market trading after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) rose 35.7% to $3.99 in pre-market trading after jumping around 56% on Friday.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares gained 22.7% to $0.76 in pre-market trading after gaining 6% on Friday.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 22.1% to $0.5133 in pre-market trading. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 19.4% to $0.5395 in pre-market trading after gaining 11% on Friday.</li>
<li>Ambipar Emergency Response (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBI#NYSE">AMBI</a>) gained 15.5% to $5.34 in pre-market trading after jumping 29% on Friday.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares gained 14.1% to $0.3371 in pre-market trading. TransCode Therapeutics 13G filing showed 3i, LP reported a 9.9% stake in the company, as of July 23.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 11.4% to $7.51 in pre-market trading. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares fell 37.4% to $13.28 in pre-market trading after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined 34% to $0.1690 in pre-market trading after gaining 6% on Friday.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 22.1% to $0.1488 in pre-market trading after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 19.6% to $1.48 in pre-market trading.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares declined 13.1% to $0.63 in pre-market trading after surging 24% on Friday.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 12.6% to $3.53 in pre-market trading. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares fell 11.6% to $0.7250 in pre-market trading after jumping 11% on Friday.</li>
<li>NuZee Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) fell 9.7% to $3.40 in pre-market trading after surging around 25% on Friday.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) shares dipped 8.8% to $9.41 in pre-market trading.</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) shares fell 6.6% to $98.29 in pre-market trading. A jury ordered Abbott to pay $495 million in compensation and damages in a baby-formula verdict, the Wall Street Journal reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">&#8216;</a></li>
</ul>

Pre-Market Outlook

AMBI

EZPW

INVO

NUZE

RNAZ

Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.

vTv Therapeutics Announces FDA Has Placed A Clinical Hold On The Cadisegliatin Clinical Program Which Includes The Ongoing CATT1 Phase 3 Trial In Type 1 Diabetes

Trading Halt: Halted at 4:01:47 p.m. ET - Trading Halt: Halt News Pending

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D &nbsp;
Cadisegliatin has been dosed in over 500 subjects to date, including 300 patients with diabetes

vTv Therapeutics Screens First Patient In CATT1 Pivotal Trial Evaluating Cadisegliatin For Type 1 Diabetes

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 20.94% to $1.42. The market value of their outstanding shares is at $26.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 31.4% to $0.38 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 25.92% to $0.8. The company's market cap stands at $2.1 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 21.86% to $0.5. The market value of their outstanding shares is at $31.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock fell 21.76% to $2.59. The market value of their outstanding shares is at $30.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 16.67% to $0.23. The market value of their outstanding shares is at $14.4 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 16.16% to $1.61. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AVGR

CLDI

CYCN

NNVC

STRM

TBIO

TCON

THMO

12 Health Care Stocks Moving In Wednesday's Intraday Session

&nbsp;Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon's previous orphan drug designation for the treatment of glioblastoma, received in early 2023.

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By vtv Therapeutics, Which Cantex Licensed Worldwide Rights

vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) reported quarterly losses of $(1.17) per share. This is a 51.25 percent increase over losses of $(2.40) per share from the same period last year. The company reported $1.00 million in sales this quarter.

vTv Therapeutics Q1 EPS $(1.17) Up From $(2.40) YoY, Sales $1.00M

vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) reported quarterly losses of $(1.67) per share. This is a 26.75 percent increase over losses of $(2.28) per share from the same period last year.

vTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY

<h3>Gainers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock moved upwards by 13.17% to $15.55. The company's market cap stands at $32.4 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock increased by 9.09% to $2.16. The company's market cap stands at $391.3 million. The company's, Q4 earnings came out today. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock increased by 7.32% to $6.01. The company's market cap stands at $391.4 million. The company's, Q4 earnings came out today. </li>
<li>YS Biopharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YS#NASDAQ">YS</a>) stock rose 6.36% to $0.65. The market value of their outstanding shares is at $122.1 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares increased by 6.1% to $4.17. The company's market cap stands at $245.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 22.2% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 12.56% to $8.08. The company's market cap stands at $440.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares declined by 10.39% to $1.64. The company's market cap stands at $209.0 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 8.8% to $0.83. The market value of their outstanding shares is at $45.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock fell 8.42% to $10.89. The company's market cap stands at $40.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares fell 8.01% to $8.5. The market value of their outstanding shares is at $166.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALDX

CARA

CERS

CMAX

CMPX

Envoy Medical, Inc. - Class A Common Stock

COCH

HSCS

MRNS

NKGN

SOPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

vTv Therapeutics Announces FDA Submission For Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) just reported results for the first quarter of 2024.<ul><li>vTv Therapeutics reported earnings per share of -$1.17.</li><li>The company reported revenue of $1.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/vtvt-stock-earnings-vtv-therapeutics-for-q1-of-2024/">VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024

Cantex Pharmaceuticals receives FDA Orphan Drug Designation for its pancreatic cancer treatment

Goldman Sachs raises obesity drug market estimate to $130B

FDA places clinical hold on vTv's cadisegliatin clinical program

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
VTv Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is falling hard on Monday after the Food and Drug Administration (FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on its cadisegliatin clinical program.



According to a news release from the company, that hold includes its TT1 Phase 3 trial in type 1 diabetes. The hold was put in place following a chromatographic signal in a human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin.



This clinical hold requires vTv Therapeutics to conduct an in vitro study before it can resume its trial. That will have it seeking to characterize the signal to satisfy the FDA&rsquo;s requirements.



VTv Therapeutics chairman, president and CEO Paul Sekhri said the following about the clinical hold.




&ldquo;Patient safety is our top priority, and we appreciate the thoroughness of the FDA to better understand this signal. We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible.&rdquo;




<h2>How This Affects VTVT Stock Today</h2>



With this news comes strong trading of VTVT shares on Monday. That has more than 10,000 shares changing hands. While that may not seem like much, the company&rsquo;s daily average trading volume is just above it at roughly 15,000 shares.



VTVT stock is down 45.7% as of Monday morning.



Investors will want to keep reading for more of the most recent stock market stories today!



We have all of the hottest market new ready to go on Monday! A few examples include why shares of Lipella Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) and Planet Image&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock are up, as well as the biggest pre-market stock movers this morning. All of this info is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-lipella-pharmaceuticals-lipo-stock-up-149-today/">Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-planet-image-yibo-stock-up-53-today/">Why Is Planet Image (YIBO) Stock Up 53% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Monday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-vtv-therapeutics-vtvt-stock-down-46-today/">Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LuxUrban Hotels&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) stock is taking a beating on Monday after the home leasing and rental company <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">priced a public offering</a> of its shares.



LuxUrban Hotels priced 11,573,333 shares of LUXH stock at 15 cents each in this public offering. It also granted the underwriters of the offering a 30-day option to acquire another 15% of shares sold in this offering.



LuxUrban Hotels is expecting gross proceeds of $1,736,000 or $1,996,400 from this offering depending on if rights are exercised. The company says it intends to use these funds for working capital and other general corporate purposes.



<h2>What This Means for LUXH Stock</h2>



A public offering increases the total number of outstanding shares on the market. That means it dilutes the stakes of current investors in LUXH. This is one of the reasons why LuxUrban Hotels stock is dropping today.



On top of that is the company&rsquo;s stock price of 15 cents per share in the offering. That&rsquo;s a decent discount over its prior closing price of 19 cents per share. It makes sense the stock would fall with this offering devaluing LUXH shares.



LUXH stock is down 12.2% as of Monday morning.



There are plenty more stock market stories traders will want to read about below!



We have all of the hottest stock market news investors need to know about on Monday! That includes everything happening with shares of vTv Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock, Lipella Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) stock and Planet Image&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock today. All of this news is ready to go at the links below!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-vtv-therapeutics-vtvt-stock-down-46-today/">Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-lipella-pharmaceuticals-lipo-stock-up-149-today/">Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-planet-image-yibo-stock-up-53-today/">Why Is Planet Image (YIBO) Stock Up 53% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-luxurban-hotels-luxh-stock-down-12-today/">Why Is LuxUrban Hotels (LUXH) Stock Down 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is LuxUrban Hotels (LUXH) Stock Down 12% Today?

vTv Therapeutics GAAP EPS of -$0.81

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) just reported results for the second quarter of 2024.<ul><li>vTv Therapeutics reported earnings per share of -81 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vtvt-stock-earnings-vtv-therapeutics-for-q2-of-2024/">VTVT Stock Earnings: vTv Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTVT Stock Earnings: vTv Therapeutics Reported Results for Q2 2024

vTv Therapeutics ( ($VTVT) ) has issued an update. OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending t...

vTv Therapeutics Faces License Agreement Termination

AMGN

BHVN

CREV

GPCR

NONOF

NRBO

NTBL

OMGA

PAPL

RYTM

VCNX

VKTX

Press Releases

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Comments

vTv Therapeutics

Notizie

Ultime notizie per vTv Therapeutics (NASDAQ:VTVT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO